Revivo Therapeutics Organizes as a Delaware Corporation with North Carolina Headquarters

Following the agreement in principle for technology transfer agreement between the University of Illinois at Chicago and Queens University, Revivo announced its incorporation for the purpose of advancing the technology surrounding Nomethiazoles as a new class of therapeutic agents, targeting neurobehavioral function, cognitive enhancement and the reduction of disease progression.